Seegene

Seegene Capital Expenditures

The Capital Expenditures (CapEx) of Seegene (096530.KQ) as of Nov 22, 2026 is -40.47 B KRW. In the previous year, Capital Expenditures (CapEx) was -43.63 B KRW — a change of -7.25% (higher).

Capital Expenditures

-40.47 BKRW

YoY

-7.25%

Last updated:

Capital Expenditures (CapEx) of Seegene is 2025 -40.47 B KRW. Capital Expenditures (CapEx) of Seegene was 2024 -43.63 B KRW. It decreases by -7.25% higher compared to the previous year.

The Seegene Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-2.93 B KRW
Jan 1, 2019
-4.07 B KRW
Jan 1, 2020
-174.03 B KRW
Jan 1, 2021
-61.66 B KRW
Jan 1, 2022
-63.26 B KRW
Jan 1, 2023
-31.88 B KRW
Jan 1, 2024
-43.63 B KRW
Jan 1, 2025
-40.47 B KRW
The Seegene Capital Expenditures history
YEARCapital ExpendituresYoY
-40.47 BKRW-7.25%
-43.63 BKRW+36.85%
-31.88 BKRW-49.61%
-63.26 BKRW+2.61%
-61.66 BKRW-64.57%
-174.03 BKRW+4,181.00%
-4.07 BKRW+38.70%
-2.93 BKRW-39.34%
-4.83 BKRW-54.91%
-10.72 BKRW+39.78%
-7.67 BKRW+190.52%
-2.64 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene, Inc. generates revenue through the manufacturing and distribution of molecular diagnostics and reagents. The company offers infectious pathogens inspection products, including those for allergic respiratory pathogens, sexually transmitted diseases, and human papilloma virus (HPV), alongside drug resistance, single nucleotide polymorphisms (SNP), and somatic mutation cancer inspection products. It also provides automatic real-time detection instruments under the brand names Seeplex, Anyplex, and Magicplex. The firm serves both domestic and overseas markets with these products. The primary customers for Seegene's products are healthcare providers and laboratories requiring diagnostic solutions. The company's product portfolio targets specific medical needs such as infectious disease testing and cancer diagnostics. Its brands Seeplex, Anyplex, and Magicplex are used across various diagnostic applications, including respiratory and sexually transmitted disease testing. The firm's focus on molecular diagnostics positions it within the healthcare sector for specialized testing services. Seegene's revenue streams are derived from the sale of its branded diagnostic products and instruments. The company's domestic and overseas market distribution strategy supports its business model, with Seeplex, Anyplex, and Magicplex serving as key product lines. The firm's offerings cater to the growing demand for accurate and efficient molecular diagnostic solutions in healthcare settings. Seegene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seegene stock

Capital Expenditures (CapEx) of Seegene is -40.47 B KRW in 2025.

Capital Expenditures (CapEx) of Seegene changed from -43.63 B KRW to -40.47 B KRW, representing a -7.25% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Seegene since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Seegene

All Key Metrics — Seegene